Sign In
Buy PRNB
$100.05
+0 (+0%)
At Close: May 27, 2022
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ironwood Pharma (IRWD), EyePoint Pharmaceuticals (EYPT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ironwood Pharma (IRWD
Principia Biopharma: Flawed Mechanism Of Action, Weak Phase 2 Results Point To Worthless Pipeline
05:20pm, Monday, 27'th Jan 2020
Principia is dramatically overvalued because its core strategy – treating autoimmune diseases with BTK inhibitors – doesn't appear to work. BTK inhibitors halt
The Cutting Edge Of Systematic Investing
05:48pm, Tuesday, 21'st Jan 2020
Systematic or Quantitative Investing continues to be a bigger part of the market as it delivers stronger market-beating returns fairly consistently. Experts oft
Zacks Investment Research Lowers Principia Biopharma (NASDAQ:PRNB) to Hold
09:58am, Tuesday, 14'th Jan 2020
Zacks Investment Research cut shares of Principia Biopharma (NASDAQ:PRNB) from a buy rating to a hold rating in a report released on Saturday, Zacks.com reports. According to Zacks, “Principia Bioph
Principia Biopharma - The Future Worsens
05:00pm, Monday, 13'th Jan 2020
Phase 2 pemphigus additional data confirmed our previous concerns. ITP indication for PRN1008 remains vague. PRN2246/SAR442168 data is likely to disappoint inve
$4.35 Million in Sales Expected for Principia Biopharma Inc (NASDAQ:PRNB) This Quarter
08:46am, Monday, 13'th Jan 2020
Equities research analysts expect Principia Biopharma Inc (NASDAQ:PRNB) to post sales of $4.35 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided est
Principia Biopharma (NASDAQ:PRNB) Earns "Buy" Rating from HC Wainwright
08:56am, Saturday, 11'th Jan 2020
HC Wainwright restated their buy rating on shares of Principia Biopharma (NASDAQ:PRNB) in a research report released on Tuesday morning, The Fly reports. The brokerage currently has a price objective
Principia Announces Expansion of its BTK Franchise with PRN473 Topical
01:01pm, Thursday, 09'th Jan 2020
Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif.,.
Principia Announces Expansion of its BTK Franchise with PRN473 Topical
01:01pm, Thursday, 09'th Jan 2020
Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH...
Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases
01:01pm, Tuesday, 07'th Jan 2020
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced an expansion in the development of rilzabrutinib
Fear and loathing in Union Square: Upcoming biotech conference exposes industry dreams, issues
03:13pm, Monday, 06'th Jan 2020
As lawmakers talk about drug price controls, drug developers are simply trying to find a place to stay during the J.P. Morgan Healthcare Conference for under $1,000 a night.
Principia Updates PRN1008 Pemphigus Clinical Program
01:01pm, Monday, 30'th Dec 2019
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated diseases
Principia Biopharma Inc. (PRNB): Hedge Funds In Wait-and-See Mode
07:44pm, Friday, 13'th Dec 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a
Why Merck, Sanofi News Helped This Biotech Rocket 32% Over Three Days
09:16pm, Wednesday, 11'th Dec 2019
Principia Biopharma stock has rocketed 32% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.
